Aura Biosciences COO Susan Abu-Absi files initial beneficial ownership statement
AURA•Initial Form 3 filing
- Aura Biosciences COO Susan Abu-Absi filed an initial Form 3 with the SEC on Aug. 12, 2026.
Related News
Turn Therapeutics Q2 net loss per share widens on higher R&D costs
TTRX•
Grocery Outlet jumps after forecasting a smaller decline in annual sales
GO•
Titan America issues 10,876 shares after subscription rights exercise at USD 0.01 each
TTAM•
Logistic Properties of the Americas Q2 net operating income jumps, partly on higher rental rates
LPA•
OrbiMed Advisors acquires $10 million of BlossomHill Therapeutics common shares
BLSM•